세계의 간질환 치료제 시장 보고서(2025년)

Liver disease therapeutics involve the treatment of various liver conditions, including those caused by viruses such as hepatitis A, B, and C. These therapies are crucial for improving the quality of life for individuals affected by liver diseases and for reducing the overall burden of liver disease on healthcare systems.

The primary disease classifications within liver disease therapeutics include hepatitis, non-alcoholic fatty liver disease, alcohol-induced conditions, and liver cancer. Hepatitis denotes liver inflammation caused by infectious viruses or noninfectious agents, leading to diverse health complications, some of which can be life-threatening. Treatment modalities encompass antiviral medications, vaccines, chemotherapy, immunosuppressive agents, and corticosteroids. End-users of these therapeutics span hospitals, ambulatory surgery centers, and other sectors.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The liver diseases therapeutics market research report is one of a series of new reports from The Business Research Company that provides liver diseases therapeutics market statistics, including liver diseases therapeutics industry global market size, regional shares, competitors with a liver diseases therapeutics market share, detailed liver diseases therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver diseases therapeutics industry. This liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver diseases therapeutics market size has grown strongly in recent years. It will grow from $14.16 billion in 2024 to $15.18 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to high prevalence of liver diseases, alcohol consumption patterns, advancements in diagnostics, obesity and metabolic syndrome, awareness and screening programs, government initiatives for hepatitis control.

The liver diseases therapeutics market size is expected to see strong growth in the next few years. It will grow to $22.08 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to precision medicine approaches, innovations in RNA therapeutics, focus on fibrosis treatments, patient advocacy and support groups, development of vaccines for hepatitis, regulatory support for orphan drugs. Major trends in the forecast period include advancements in treatment for hepatitis c, emergence of novel therapies for liver fibrosis, exploration of immunotherapies, telemedicine and remote monitoring, focus on nutritional interventions.

The forecast of 9.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of novel antifibrotic drugs and biliary drainage stents imported from Germany and Singapore, thereby limiting treatment options for chronic liver conditions and elevating gastroenterology care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of liver diseases is anticipated to drive the growth of the liver disease therapeutics market in the coming years. Liver disease encompasses any condition that affects the liver, and liver disease therapeutics provide various treatment options to address these conditions. For example, a report from the Office for Health Improvement and Disparities, a UK-based government department, indicated that in 2022, the mortality rate from liver disease for individuals under 75 in England reached 21.4 per 100,000 population. Notably, there were 6,664 premature deaths among males compared to 3,929 among females. Thus, the rising incidence of liver diseases is a significant factor propelling the growth of the liver disease therapeutics market.

The expanding geriatric population is expected to drive the growth of the low-density polyethylene (LDPE) market in the coming years. The geriatric population refers to older individuals or senior citizens who have reached or surpassed a certain age, typically associated with retirement and the later stages of life. LDPE is increasingly utilized in the pharmaceutical industry to package liver disease therapeutics, which address liver-related health issues and improve the quality of life for elderly individuals. For instance, a report from the Population Reference Bureau, a Kenya-based nonprofit organization, projected that the population of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. During the same period, this age group's share of the overall population is expected to grow from 17% to 23%. Therefore, the expanding pharmaceutical industry, catering to the needs of the aging population, is contributing to the growth of the low-density polyethylene market.

Strategic partnerships represent a prominent trend in the liver disease therapeutics market. Leading companies within this sector are engaging in collaborations to fortify their positions. For instance, in January 2022, Aligos Therapeutics Inc., a US-based biopharmaceutical company, partnered with Merck & Co. to develop oligonucleotide therapies for non-alcoholic steatohepatitis. Similarly, in January 2021, Novartis collaborated with Alnylam to develop liver-targeted therapies as potential alternatives to transplantation for patients experiencing liver failure.

Prominent players in the liver disease therapeutics market prioritize innovative technologies, notably artificial intelligence (AI), to enhance patient care. AI applications in liver disease therapeutics involve sophisticated computational algorithms and machine learning techniques to analyze medical data, facilitating early detection, precise diagnosis, and personalized treatment strategies for liver diseases. For example, Predictive Health Intelligence, a UK-based healthcare information management company, unveiled hepatoSIGHT in February 2023. hepatoSIGHT, an AI-powered tool, predicts liver fibrosis in chronic liver disease patients, aiding case-finding and cohort mapping. It offers comprehensive data analysis, machine learning algorithms, real-time risk stratification, and user-friendly interfaces for efficient patient identification within seconds.

In September 2022, GENFIT, a biopharmaceutical company headquartered in France, completed the acquisition of Versantis for an undisclosed sum. This strategic acquisition integrates Versantis' specialized expertise in liver disease therapeutics with GENFIT's extensive knowledge in executing intricate development programs focused on liver diseases. This collaboration serves to reinforce and expedite research and development efforts, substantially broadening GENFIT's pipeline in this field. Versantis, based in Switzerland, specializes in therapeutic solutions for liver diseases.

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., AstraZeneca PLC, Gilead Sciences Inc., Endo International PLC, Alnylam Pharmaceuticals Inc., Provectus Biopharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

North America was the largest region in the liver diseases therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liver diseases therapeutics market includes revenues earned by entities by diagnosis such as imaging, laboratory tests, endoscopy, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liver Diseases Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liver diseases therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liver diseases therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The liver diseases therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Hepatitis; Non-Alcoholic Fatty Liver Disease; Alcohol-Induced; Liver Cancer
• 2) By Treatment: Antiviral; Vaccines; Chemotherapy; Immunosuppressive Agents; Corticosteroids
• 3) By End User: Hospitals; Ambulatory Surgery Centers; Other End Users
• Subsegments:
• 1) By Hepatitis: Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D
• 2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH); Simple Fatty Liver
• 3) By Alcohol-Induced Liver Disease: Alcoholic Hepatitis; Alcoholic Cirrhosis
• 4) By Liver Cancer: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma
• Companies Mentioned: Astellas Pharma Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Novartis AG; GlaxoSmithKline PLC; Abbott Laboratories Inc.; Pfizer Inc.; Sanofi SA; Johnson & Johnson Services Inc.; Bayer AG; AbbVie Inc.; Takeda Pharmaceutical Company Limited; Valeant Pharmaceuticals; Watson Pharmaceuticals Inc.; AstraZeneca PLC; Gilead Sciences Inc.; Endo International PLC; Alnylam Pharmaceuticals Inc.; Provectus Biopharmaceuticals Inc.; Intercept Pharmaceuticals Inc.; Conatus Pharmaceuticals Inc.; CymaBay Therapeutics Inc.; Viking Therapeutics Inc.; Madrigal Pharmaceuticals Inc.; NGM Biopharmaceuticals Inc.; Arrowhead Pharmaceuticals Inc.; Dicerna Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Enanta Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liver Diseases Therapeutics Market Characteristics

3. Liver Diseases Therapeutics Market Trends And Strategies

4. Liver Diseases Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Liver Diseases Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Liver Diseases Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Liver Diseases Therapeutics Market Growth Rate Analysis
• 5.4. Global Liver Diseases Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Liver Diseases Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Liver Diseases Therapeutics Total Addressable Market (TAM)

6. Liver Diseases Therapeutics Market Segmentation

• 6.1. Global Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis
• Non-Alcoholic Fatty Liver Disease
• Alcohol-Induced
• Liver Cancer
• 6.2. Global Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiviral
• Vaccines
• Chemotherapy
• Immunosuppressive Agents
• Corticosteroids
• 6.3. Global Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgery Centers
• Other End Users
• 6.4. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Hepatitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis A
• Hepatitis B
• Hepatitis C
• Hepatitis D
• 6.5. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Non-Alcoholic Fatty Liver Disease (NAFLD), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Alcoholic Steatohepatitis (NASH)
• Simple Fatty Liver
• 6.6. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Alcohol-Induced Liver Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alcoholic Hepatitis
• Alcoholic Cirrhosis
• 6.7. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Liver Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatocellular Carcinoma (HCC)
• Cholangiocarcinoma

7. Liver Diseases Therapeutics Market Regional And Country Analysis

• 7.1. Global Liver Diseases Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Liver Diseases Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liver Diseases Therapeutics Market

• 8.1. Asia-Pacific Liver Diseases Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liver Diseases Therapeutics Market

• 9.1. China Liver Diseases Therapeutics Market Overview
• 9.2. China Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liver Diseases Therapeutics Market

• 10.1. India Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liver Diseases Therapeutics Market

• 11.1. Japan Liver Diseases Therapeutics Market Overview
• 11.2. Japan Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liver Diseases Therapeutics Market

• 12.1. Australia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liver Diseases Therapeutics Market

• 13.1. Indonesia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liver Diseases Therapeutics Market

• 14.1. South Korea Liver Diseases Therapeutics Market Overview
• 14.2. South Korea Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liver Diseases Therapeutics Market

• 15.1. Western Europe Liver Diseases Therapeutics Market Overview
• 15.2. Western Europe Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liver Diseases Therapeutics Market

• 16.1. UK Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liver Diseases Therapeutics Market

• 17.1. Germany Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liver Diseases Therapeutics Market

• 18.1. France Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liver Diseases Therapeutics Market

• 19.1. Italy Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liver Diseases Therapeutics Market

• 20.1. Spain Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liver Diseases Therapeutics Market

• 21.1. Eastern Europe Liver Diseases Therapeutics Market Overview
• 21.2. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liver Diseases Therapeutics Market

• 22.1. Russia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liver Diseases Therapeutics Market

• 23.1. North America Liver Diseases Therapeutics Market Overview
• 23.2. North America Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liver Diseases Therapeutics Market

• 24.1. USA Liver Diseases Therapeutics Market Overview
• 24.2. USA Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liver Diseases Therapeutics Market

• 25.1. Canada Liver Diseases Therapeutics Market Overview
• 25.2. Canada Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liver Diseases Therapeutics Market

• 26.1. South America Liver Diseases Therapeutics Market Overview
• 26.2. South America Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liver Diseases Therapeutics Market

• 27.1. Brazil Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liver Diseases Therapeutics Market

• 28.1. Middle East Liver Diseases Therapeutics Market Overview
• 28.2. Middle East Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liver Diseases Therapeutics Market

• 29.1. Africa Liver Diseases Therapeutics Market Overview
• 29.2. Africa Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liver Diseases Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Liver Diseases Therapeutics Market Competitive Landscape
• 30.2. Liver Diseases Therapeutics Market Company Profiles
  • 30.2.1. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Liver Diseases Therapeutics Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline PLC
• 31.2. Abbott Laboratories Inc.
• 31.3. Pfizer Inc.
• 31.4. Sanofi SA
• 31.5. Johnson & Johnson Services Inc.
• 31.6. Bayer AG
• 31.7. AbbVie Inc.
• 31.8. Takeda Pharmaceutical Company Limited
• 31.9. Valeant Pharmaceuticals
• 31.10. Watson Pharmaceuticals Inc.
• 31.11. AstraZeneca PLC
• 31.12. Gilead Sciences Inc.
• 31.13. Endo International PLC
• 31.14. Alnylam Pharmaceuticals Inc.
• 31.15. Provectus Biopharmaceuticals Inc.

32. Global Liver Diseases Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liver Diseases Therapeutics Market

34. Recent Developments In The Liver Diseases Therapeutics Market

35. Liver Diseases Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Liver Diseases Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Liver Diseases Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Liver Diseases Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer